| Title: |
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial |
| Authors: |
Dasgupta, Indranil; Meadowcroft, Amy M; Bhatt, Purav R; Acharya, Anjali; Aarup, Michael; Correa-Rotter, Ricardo; Gupta, Shruti; Kher, Vijay K; Neto, Osvaldo M Viera; Rastogi, Anjay; Ots-Rosenberg, Mai; Rayner, Brian; Wong, Muh Geot; Shah, Sunay; Taft, Lin; Singh, Ajay K |
| Source: |
Dasgupta, I, Meadowcroft, A M, Bhatt, P R, Acharya, A, Aarup, M, Correa-Rotter, R, Gupta, S, Kher, V K, Neto, O M V, Rastogi, A, Ots-Rosenberg, M, Rayner, B, Wong, M G, Shah, S, Taft, L & Singh, A K 2025, 'Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial', Nephrology Dialysis Transplantation, vol. 40, no. 7, pp. 1332-1341. https://doi.org/10.1093/ndt/gfae273 |
| Publication Year: |
2025 |
| Collection: |
University of Southern Denmark: Research Output / Syddansk Universitet |
| Description: |
BACKGROUND AND HYPOTHESIS: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD). METHODS: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients). In PD patients, prespecified analyses of the co-primary endpoints of mean change in hemoglobin from baseline to Weeks 28-52 using an ANOVA model and first occurrence of a major cardiovascular event (MACE) using a Cox proportional hazards model were conducted. The secondary endpoints were average monthly intravenous iron dose to Week 52 and treatment-emergent adverse events. Additional post hoc analyses were conducted. RESULTS: Overall, 340 PD patients (daprodustat n = 171, darbepoetin alfa n = 169) were randomized. Mean age was 53.6 years (±14 SD), 55% male, 56% White. For daprodustat and darbepoetin alfa groups respectively, mean change in hemoglobin was 0.38 and 0.23 g/dL [adjusted mean difference 0.15, 95% confidence interval (CI), -0.04, 0.34], and first occurrence of adjudicated MACE occurred in 40 (23.4%) and 46 (27.2%) patients (HR 0.84; 95% CI, 0.55-1.28). No heterogeneity was observed between PD and HD patients for these endpoints in ASCEND-D. Serum hepcidin was lower with daprodustat; there was no difference in other iron parameters, intravenous iron usage, transfusion requirement, blood pressure, or quality of life. There were no differences in adverse events or incidence of peritonitis between the groups. CONCLUSIONS: This subgroup analysis of the ASCEND-D trial demonstrated comparable efficacy and safety of daprodustat versus darbepoetin alfa in PD patients, supporting its use in the treatment of anemia in these patients. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
0931-0509; 1460-2385 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39817409; info:eu-repo/semantics/altIdentifier/pissn/0931-0509; info:eu-repo/semantics/altIdentifier/eissn/1460-2385 |
| DOI: |
10.1093/ndt/gfae273 |
| Availability: |
https://portal.findresearcher.sdu.dk/da/publications/6ee1ae99-9332-4870-a88c-e545acd72ef9; https://doi.org/10.1093/ndt/gfae273; https://findresearcher.sdu.dk/ws/files/292248756/gfae273.pdf |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.C77AC375 |
| Database: |
BASE |